Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice
Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice
| dc.contributor.author | Xie, Vicki | |
| dc.contributor.author | Tong, Daochen | |
| dc.contributor.author | Wallington-Beddoe, Craig T | |
| dc.contributor.author | Bradstock, Kenneth F | |
| dc.contributor.author | Bendall, Linda J | |
| dc.date.accessioned | 2018-02-19T05:15:18Z | |
| dc.date.available | 2018-02-19T05:15:18Z | |
| dc.date.issued | 2018-02-05 | |
| dc.date.updated | 2018-02-15T06:51:46Z | |
| dc.description | © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated | |
| dc.description.abstract | Background Sphingosine kinase (SphK) 2 has been implicated in the development of a range of cancers and inhibitors of this enzyme are currently in clinical trial. We have previously demonstrated a role for SphK2 in the development of acute lymphoblastic leukemia (ALL). Methods In this and our previous study we use mouse models: in the previous study the disease was driven by the proto-oncogene BCR/ABL1, while in this study cancer risk was elevated by deletion of the tumor suppressor ARF. Results Mice lacking ARF and SphK2 had a significantly reduced incidence of ALL compared mice with wild type SphK2. Conclusions These results show that the role of SphK2 in ALL development is not limited to BCR/ABL1 driven disease extending the potential use of inhibitors of this enzyme to ALL patients whose disease have driver mutations other than BCR/ABL1." | |
| dc.identifier.citation | Xie, V., Tong, D., Wallington-Beddoe, C. T., Bradstock, K. F., & Bendall, L. J. (2018). Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice. Biomarker Research, 6(1). https://doi.org/10.1186/s40364-018-0120-4 | |
| dc.identifier.doi | https://doi.org/10.1186/s40364-018-0120-4 | |
| dc.identifier.uri | https://doi.org/10.1186/s40364-018-0120-4 | |
| dc.identifier.uri | http://hdl.handle.net/2328/37757 | |
| dc.language.iso | en | en |
| dc.publisher | BioMed Central | |
| dc.rights | © The Author(s) 2018 | |
| dc.rights.holder | The Author(s) | |
| dc.rights.license | CC-BY | |
| dc.subject | Acute lymphoblastic leukemia | |
| dc.subject | Sphingosine kinase 2 | |
| dc.subject | Mouse models | |
| dc.title | Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice | |
| dc.type | Article | en |
Files
Original bundle
1 - 1 of 1
- Name:
- 40364_2018_Article_120.pdf
- Size:
- 2.4 MB
- Format:
- Adobe Portable Document Format
- Description:
- Publisher version
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.84 KB
- Format:
- Item-specific license agreed upon to submission
- Description: